Pharma stocks plunge after Trump’s attack on drug pricing

Following president-elect Donald Trump’s plans to create a new bidding procedure for the pharmaceutical industry, shares in both pharma and biotech companies have fallen. Trump claims in his latest speech that he is looking to control drug prices and repeal and replace elements of Obamacare. Ketan Patel, manager of the EdenTree UK Equity Growth fund talks to Investment Week, discussing the future of the pharmaceutical sector following Trump’s strong rhetoric.